Néphrologie : ce qui a changé en 2025

Read full text
Authors: Giliane Nanchen, Menno Pruijm, Faïza Lamine, Dela Golshayan, Fádi Fakhouri
Cited by: 1

Abstract

Complement inhibitors are expanding their indications in nephrology. In patients with type 2 diabetes, semaglutide prevents chronic kidney disease (CKD), while retatrutide reduces albuminuria in patients with diabetes and established CKD. Obinutuzumab improves the renal response in patients with lupus nephropathy. A double dose of icodextrin did not reduce mortality, peritonitis, or hospitalization rates compared to standard peritoneal dialysis treatment, though it increased ultrafiltration. In patients on hemodialysis, using a dialysate with an intermediate potassium concentration combined with a potassium chelator appears to stabilize serum potassium levels and reduce the occurrence of arrhythmias. Xenotransplantation and ex vivo perfusion techniques are being perfected in the search for a solution to organ shortage.

Fields of Study & Subjects

Renal Transplantation Outcomes and Treatments Chronic Kidney Disease and Diabetes Organ Donation and Transplantation

Publication details

Journal / source
Revue Médicale Suisse
Publisher
Médecine et Hygiène
Volume
22
Issue
945
Pages
49–52
Publication date
1 January 2026
Language
EN